Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
Jiang ZB, Huang J, Xie C, Li X, Liu L, He J, Pan H, Huang L, Fan XX, Yao XJ, Xie Y, Li N, Liu L, He JX, Leung EL.
Jiang ZB, et al. Among authors: huang l, huang j.
Oncol Rep. 2016 Jul;36(1):365-75. doi: 10.3892/or.2016.4770. Epub 2016 Apr 26.
Oncol Rep. 2016.
PMID: 27121230